Metraipolis › archive › dc_8bb2246cc274

Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A… — Europe PMC PMID:42775329

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42775329
DOI
10.5937/jomb0-60451
License (as archived)
solo-consultazione
Archived
2026-11-05T11:28:10.893Z
SHA-256 of the archived text
6927c729c80e908cda3303bf0a9ad94afd2136b8e347555995ab311e50114fe8
Stable URL of this page
https://metraipolis.com/documento/dc_8bb2246cc274

How to cite

Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A… — Europe PMC PMID:42775329 — Europe PMC (en), https://europepmc.org/article/MED/42775329 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8bb2246cc274 (Metraipolis archive dc_8bb2246cc274, sha256 6927c729c80e908cda3303bf0a9ad94afd2136b8e347555995ab311e50114fe8)
BibTeX
@misc{dc8bb2246cc274,
  title = {Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A… — Europe PMC PMID:42775329},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42775329},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8bb2246cc274; sha256 6927c729c80e908cda3303bf0a9ad94afd2136b8e347555995ab311e50114fe8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42775329. Agents can read the archived copy with the MCP tool read_document.